Form 4: Fennec Pharmaceuticals CFO Robert Andrade Reports Share Release
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares previously restricted, increasing his total holdings to 133,633 shares.
Summary
- On April 30, 2025, Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, reported a transaction involving the release of restricted common shares.
- A total of 1,042 common shares were released from restriction.
- These shares were originally awarded on March 31, 2023.
- Following this transaction, Andrade's total beneficial ownership of Fennec Pharmaceuticals common shares is 133,633.
- The transaction was reported on May 1, 2025.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.
Key Dates
| Date | Description |
|---|---|
| 2023-03-31 | Date shares were originally awarded to Robert Andrade. |
| 2025-04-30 | Date of the transaction where 1,042 shares were released from restriction. |
| 2025-05-01 | Date the Form 4 was signed and reported. |
Keywords
Fennec Pharmaceuticals, Robert Andrade, CFO, Form 4, Beneficial Ownership, Share Release, Securities, FENC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.